Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

By The Northwire Desk — AI Analysis Jun 03, 2026 · 07:00 MDNA · 0.42 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics announced the presentation of the NEO-CYT Phase 1b trial at the 2026 ASCO Annual Meeting.
  • The trial evaluates MDNA11 combined with checkpoint inhibitors (nivolumab ± ipilimumab) as neoadjuvant therapy for high-risk, surgically resectable Stage III melanoma.
  • The study aims to surpass the current standard of care (ipilimumab + nivolumab) by leveraging MDNA11's beta-enhanced IL-2 Superkine mechanism to improve Major Pathologic Response (MPR) rates.
  • Clinical data updates for both NEO-CYT and the ongoing Phase 1/2 ABILITY-1 study are expected in the second half of 2026.
  • This follows the May 12, 2026 announcement of the first patient dosing in NEO-CYT and the May 21/28, 2026 closing of a $4.44M public offering plus an $8.0M structured financing agreement.
Material Impact
  • The ASCO presentation is a scheduled, investigator-sponsored academic update. It does not contain new clinical data, efficacy endpoints, or safety signals that would alter the investment thesis.
  • The news is a direct follow-up to the May 12 first-patient-dosing announcement and aligns with the company's stated H2 2026 data timeline.
  • The market has already priced in the capital raise (May 2026) and the clinical progression. Without specific data highlights or regulatory milestones, the presentation is incremental and expected.
  • The stock's recent decline from $1.64 to $0.42 reflects broader biotech sentiment, dilution from the $0.50/unit offering, and the absence of near-term catalysts. This release does not reverse that trajectory.
MDNA · Price
Company Overview
  • Medicenna Therapeutics is a clinical-stage biotechnology company focused on engineered cytokine therapies for oncology and inflammatory diseases.
  • Flagship asset: MDNA11, a long-acting, beta-enhanced IL-2 Superkine designed to preferentially activate CD8+ T cells and NK cells while sparing regulatory T cells (Tregs).
  • Pipeline:
  • MDNA11: Phase 1/2 ABILITY-1 study in advanced solid tumors; Phase 1b NEO-CYT neoadjuvant melanoma trial.
  • MDNA113: First-in-class tumor-anchored, conditionally activated anti-PD-1 x IL-2 bifunctional superkine. Preclinical data shows superior tolerability in non-human primates. IND filing targeted for H2 2026.
  • Bizaxofusp (MDNA55): IL-4 Empowered Superkine for recurrent glioblastoma. Phase 2b data showed median OS of 13.6 months vs 7 months standard care. Seeking partnership.
  • Development strategy relies on combination immunotherapy regimens and expanding into earlier-line settings (neoadjuvant) and broader solid tumor indications.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 19, 2026 · 07:00

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings